Has epigenetic age reversal been demonstrated?

In cells and in mice, yes: Ocampo et al. (Cell 2016) ameliorated age-associated hallmarks in living mice, Lu et al. (Nature 2020) restored vision, and Gill et al. (eLife 2022) wound the methylation clock of human fibroblasts back by roughly 30 years. In humans, no rejuvenation therapy has completed clinical proof of epigenetic age reversal — anyone claiming otherwise is selling ahead of the data.

What does the -100 in the site's name mean?

The aspiration behind the field: if epigenetic age can be measured and reset, a century of healthy lifespan stops being fantasy and becomes an engineering target. It is a direction, not a promise.

What is Panacea Bio Chem's role?

Panacea runs a research programme in peptide- and enzyme-mediated epigenetic modulation, led by Bogdan Dicoias — designer molecules aimed at the writing and erasing machinery of the epigenome. It is a research direction: Panacea claims no rejuvenation results, and publishes its position so the boundary between programme and hype stays visible.

Are there human trials of partial reprogramming?

One is registered on ClinicalTrials.gov: NCT07290244, Life Biosciences' ER-100 — a Phase 1 single-dose open-label tolerability study in which an AAV vector delivers the OSK factors (OCT4, SOX2, KLF4) into one eye of participants with optic neuropathies, recruiting since 2026-03-02 with an estimated 18 participants. No human reprogramming trial has completed and none has posted an efficacy or methylation-clock result. Registry status checked 2026-09-08 against ClinicalTrials.gov; other registries were not searched.

Longevity science · Panacea research position

Your cells forget how old they should be. Science is learning to remind them.

Q: What is epigenetic aging?

Cells keep their identity through chemical marks on the genome — above all DNA methylation — that decide which genes run. With age the pattern drifts: marks appear where they should not and vanish where they should be. That drift, measurable by DNA methylation clocks such as the one Steve Horvath published in 2013, is epigenetic aging.

Q: What is epigenetic restoration?

The research goal of writing the youthful epigenetic pattern back without erasing cell identity. The strongest experimental route so far is partial reprogramming: brief, controlled expression of Yamanaka factors (OSK or OSKM) that resets methylation age in cells and, in animal studies, restored tissue function — for example vision in the Sinclair lab's 2020 Nature study.

Aging is not only wear and tear — it is amnesia. The genome survives intact, but the chemical annotations that tell each cell which genes to run fade, smear and drift. Epigenetic restoration is the field asking the most audacious question in biology: if the pattern was written once, can it be written back? The "-100" is the aspiration — a century of healthy lifespan.

DNA double helix carrying methyl-group marks — the annotations that define epigenetic age — Panacea Bio Chem — Scientific illustration — not experimental imagery.

What epigenetic aging actually is

Every cell in your body carries the same genome. A neuron and a skin cell differ not in the book they own, but in which pages are bookmarked. The bookmarks are epigenetic marks — chiefly methyl groups stamped onto cytosines at CpG sites — and they are laid down, read and erased by dedicated molecular machinery. Aging, in the epigenetic view, is the slow corruption of that annotation layer.

The clock that started it all

In 2013, Steve Horvath at UCLA showed that methylation levels at just 353 CpG sites predict the biological age of virtually any human tissue — the "Horvath clock". For the first time, aging had a ruler. Every claim of rejuvenation since has had to answer to it.

Information loss, not just damage

David Sinclair's lab at Harvard Medical School argues (Cell, 2023) that disrupting the epigenome — without touching the DNA sequence — is itself sufficient to drive aging in mice. Break the filing system, and a young animal turns old. Restore it, and the old tissue remembers.

The reset button exists

In 2006 Shinya Yamanaka at Kyoto University converted adult cells back to stem cells with four factors — Oct4, Sox2, Klf4, c-Myc. Full reprogramming erases identity. The discovery that changed longevity science: partial reprogramming — a short pulse, then stop — resets age while the cell remains itself.

Restoration in living animals

Ocampo and colleagues in Juan Carlos Belmonte's lab at the Salk Institute (Cell, 2016) pulsed OSKM cyclically in mice and ameliorated age-associated hallmarks. Lu and colleagues in the Sinclair lab (Nature, 2020) restored vision in old and glaucomatous mice with OSK — no c-Myc. The mouse data is real. The human data does not exist yet.

Restoration — and the hype around it

This field now attracts billions of dollars, and with the money comes noise. Where the science ends and the marketing begins:

What "restoration" does NOT yet mean

No therapy has completed clinical proof of epigenetic age reversal in humans. Full stop.
A methylation clock moving in a small uncontrolled trial is a signal, not a result — clocks are proxies, and different clocks disagree.
Full reprogramming in the wrong dose causes teratomas — tumours of lost identity. The margin between "rejuvenated" and "no longer a liver cell" is the entire problem.
Supplements marketed as "epigenetic age reversal" have no controlled evidence behind the claim.

What the record DOES show

Methylation age is measurable, reproducible, and predicts mortality better than birthdays (Horvath 2013 and successors).
Partial reprogramming resets the clock in human cells (~30 years of reversal: Gill et al., Babraham Institute, eLife 2022) and restores function in mouse tissues.
Chemical reprogramming — small molecules instead of genes — exists (Hongkui Deng's lab, Peking University, Science 2013), hinting that a drug-like route is physically possible.
Serious capital agrees: Altos Labs launched in 2022 with ~$3 billion; Calico (Alphabet) since 2013; Retro Biosciences raised $180M from Sam Altman targeting +10 healthy years.

Human trials: the registry status

Everything above is cells and mice. What about humans? This page now carries the registry check itself — dated, scoped, and re-run quarterly.

One registered trial, zero completed — checked 2026-09-08

A search of ClinicalTrials.gov (API v2, 2026-09-08) for partial epigenetic reprogramming — by intervention, mechanism and sponsor terms — returns exactly one registered interventional human trial: NCT07290244, Life Biosciences' ER-100. An engineered AAV delivers the OSK trio (OCT4, SOX2, KLF4 — three of the four Yamanaka factors) into one eye of participants with open-angle glaucoma or NAION, with doxycycline switching the factors on for 56 days. It is a Phase 1, single-dose, open-label tolerability study: 18 participants estimated, recruiting since 2026-03-02, primary completion estimated May 2027. Registry record.

The same check finds no completed reprogramming trial, no posted efficacy or methylation-clock result, no Phase 2 or 3, and no systemic (whole-body) administration in humans. The first human experiment has begun; the first human result has not. Scope: this check covers ClinicalTrials.gov only — other national and WHO registries, company pipeline pages and preprints were not searched.

Epigenetic age dial turning backward — the restoration concept — Panacea Bio Chem

Panacea's position: modulation with designer molecules

The field's giant experiments use transcription-factor genes delivered by viruses — powerful, but hard to dose and hard to target. Panacea Bio Chem's research programme, led by Bogdan Dicoias, explores a complementary route: peptide- and enzyme-mediated epigenetic modulation — designer amino acid chain (AAC) molecules aimed at the writers, erasers and readers of the epigenome, where dosing can be titrated, stopped, and targeted tissue by tissue.

We state the boundary plainly: this is a research direction, not a product and not a therapy. Panacea claims no rejuvenation results. What we publish here is the scientific landscape and our position in it; programme details remain Panacea intellectual property until peer-reviewed disclosure.

Research programme · no clinical claims · no fabricated data

Bogdan Dicoias — Biochemist, AAC Designer, Director of Panacea Bio Chem

"A gene therapy that rewinds the clock is a thunderstorm — magnificent, and impossible to aim at a single cell. A peptide is a key cut for one lock. Epigenetic restoration will not be won by the loudest intervention but by the most precise one, and precision is what designer amino acid chains are for."

Bogdan Dicoias — Biochemist · AAC Designer · Panacea Bio Chem Ltd

Frequently asked questions

What is epigenetic aging?

Cells keep identity through methylation marks on the genome; with age the pattern drifts. That drift — measurable by DNA methylation clocks like Horvath's 2013 multi-tissue clock — is epigenetic aging.

What is epigenetic restoration?

Writing the youthful epigenetic pattern back without erasing cell identity. The leading experimental route is partial reprogramming with Yamanaka factors; chemical routes exist in principle.

Has age reversal been demonstrated?

In cells and mice, yes — Ocampo 2016, Lu 2020, Gill 2022. In humans, no therapy has completed clinical proof. More on the Questions page.

What does the -100 mean?

The aspiration: epigenetic age reversal toward a century of healthy lifespan. A direction, not a promise — the credited timeline is on The Story.

Are there human trials yet?

One is registered: NCT07290244, Life Biosciences' ER-100 — a Phase 1 single-dose tolerability study delivering OSK by AAV into one eye, recruiting since March 2026. None has completed, and no results are posted. The dated registry status is above; the Questions page carries the full answer.